Magazine article Nutrition Health Review

Drug for Parkinson's Disease Linked to Heart Valve Damage

Magazine article Nutrition Health Review

Drug for Parkinson's Disease Linked to Heart Valve Damage

Article excerpt

Permax® (pergolide, Eli Lilly) is a dopamine agonist and was approved by the U.S. Food and Drug Administration (F.D.A.) in 1988 as an adjunctive therapy with L-dopa for patients with Parkinson's disease (PD). PD is a progressive neurological disorder resulting from the degeneration of neurons in a region of the brain that controls movement. Valvular heart disease was first described in association with this drug in 2002. In patients with valve regurgitation, the heart valves do not close tightly, allowing blood to flow backward across the valve. Symptoms include shortness of breath, fatigue, and heart palpitations.

In 2003, the F.D.A. asked the manufacturer and its generic counterparts made by Par and Teva to add heart valve damage to the warnings section of the agent's labeling, which was upgraded to a black-box warning in 2006. In March 2007, the F.D.A. asked Eli Lilly to take Permax® off the market following publication of two additional studies in the January 4, 2007, issue of the New England Journal of Medicine, indicated high rates of valve leakage in patients prescribed Permax®. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.